Skip to Content

Press Releases

Date Title Additional Format
Sep 20, 2006
Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Sep 14, 2006
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Sep 11, 2006
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sep 08, 2006
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference
Aug 17, 2006
Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet
Aug 13, 2006
Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens
Aug 03, 2006
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
Jul 26, 2006
Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results
Jun 30, 2006
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
Jun 30, 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
May 23, 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients
May 21, 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
May 17, 2006
Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
May 16, 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
May 11, 2006
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
Apr 29, 2006
Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
Apr 26, 2006
New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
Apr 25, 2006
Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
Apr 05, 2006
Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
Mar 23, 2006
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
Displaying 721 - 740 of 831